Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Liabilities: 2009-2025

Historic Total Liabilities for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $125.9 million.

  • Northwest Biotherapeutics' Total Liabilities rose 34.52% to $125.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.9 million, marking a year-over-year increase of 34.52%. This contributed to the annual value of $105.7 million for FY2024, which is 41.09% up from last year.
  • Northwest Biotherapeutics' Total Liabilities amounted to $125.9 million in Q3 2025, which was up 8.33% from $116.2 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Total Liabilities registered a high of $385.7 million during Q1 2021, and its lowest value of $64.1 million during Q2 2023.
  • Its 3-year average for Total Liabilities is $90.9 million, with a median of $86.0 million in 2024.
  • Per our database at Business Quant, Northwest Biotherapeutics' Total Liabilities surged by 773.03% in 2021 and then slumped by 68.52% in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Total Liabilities (Quarterly) stood at $164.2 million in 2021, then declined by 16.93% to $136.4 million in 2022, then slumped by 45.06% to $74.9 million in 2023, then skyrocketed by 41.09% to $105.7 million in 2024, then spiked by 34.52% to $125.9 million in 2025.
  • Its last three reported values are $125.9 million in Q3 2025, $116.2 million for Q2 2025, and $112.3 million during Q1 2025.